"UK Scientists Develop Breakthrough Drug Starving Asbestos-Linked Cancer"

A new drug called pegargiminase has shown promise in a phase 3 clinical trial for treating pleural mesothelioma, a deadly cancer caused by exposure to asbestos. Patients who received the drug alongside conventional chemotherapy were four times as likely to be alive after three years compared to those who received a placebo. The drug works by degrading an amino acid called arginine, which many mesothelioma cells lack the ability to produce, leading to their struggle to function. The drug is also being assessed in clinical trials for other types of cancer.